Acrivon Therapeutics, Inc. Common Stock
ACRV · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $13 | $16 | $15 | $18 |
| G&A Expenses | $0 | $6 | $6 | $0 |
| SG&A Expenses | $6 | $6 | $6 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | -$0 | $0 |
| Operating Expenses | $19 | $22 | $21 | $25 |
| Operating Income | -$20 | -$23 | -$22 | -$25 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $2 | $2 | $2 |
| Pre-Tax Income | -$18 | -$21 | -$20 | -$23 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$18 | -$21 | -$20 | -$23 |
| % Margin | – | – | – | – |
| EPS | -0.47 | -0.55 | -0.51 | -0.6 |
| % Growth | 14.5% | -7.8% | 15% | – |
| EPS Diluted | -0.47 | -0.55 | -0.51 | -0.6 |
| Weighted Avg Shares Out | 39 | 38 | 38 | 38 |
| Weighted Avg Shares Out Dil | 39 | 38 | 38 | 38 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $2 | $2 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$18 | -$21 | -$19 | -$23 |
| % Margin | – | – | – | – |